Steel Dynamics, Inc. (NASDAQ: STLD), a company engaged in steel production and metal recycling in North America, has provided guidance for the third quarter ending September 30, 2024.
- The company said it expects earnings in the range of $1.94 per share to $1.98 per share for the third quarter, compared to $3.47 per share in the prior-year quarter.
- Profitability from steel operations is expected to be meaningfully lower in Q3 than in the second quarter of 2024
- Q3 profit from metals recycling operations is expected to be in line with earnings generated in the preceding quarter
- Earnings from steel fabrication operations are expected to be moderately lower than in Q2 2024, based on an anticipated slight decline in average realized pricing
- The order backlog remains steady, extending into the first quarter of fiscal 2025 at attractive pricing levels
- The company repurchased $307 million, or 2%, of its common shares during the third quarter, through September 11, 2024
- The third quarter 2024 earnings report is expected to come on Wednesday, October 16, 2024, after the closing bell
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
DIS Earnings: All you need to know about Walt Disney’s Q4 2025 earnings results
The Walt Disney Company (NYSE: DIS) reported its fourth quarter 2025 earnings results today. Revenues of $22.5 billion were comparable to the year-ago quarter. Net income attributable to The Walt
Cisco (CSCO) reports higher Q1 revenue and earnings; results beat estimates
Network gear maker Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the first quarter of fiscal 2026, reporting higher revenue and profit. Earnings, on an adjusted basis,
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors. In an email conversation with
